Back to Search
Start Over
The tumor suppressor MIR139is silenced by POLR2M to promote AML oncogenesis
- Source :
- Leukemia; March 2022, Vol. 36 Issue: 3 p687-700, 14p
- Publication Year :
- 2022
-
Abstract
- MIR139is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show that MLL-AF9 expression in hematopoietic precursors caused epigenetic silencing of MIR139, whereas overexpression of MIR139inhibited in vitro and in vivo AML outgrowth. We identified novel miR-139targets that mediate the tumor-suppressing activities of miR-139in MLL-AF9 AML. We revealed that two enhancer regions control MIR139expression and found that the polycomb repressive complex 2 (PRC2) downstream of MLL-AF9 epigenetically silenced MIR139in AML. Finally, a genome-wide CRISPR-Cas9 knockout screen revealed RNA Polymerase 2 Subunit M (POLR2M) as a novel MIR139-regulatory factor. Our findings elucidate the molecular control of tumor suppressor MIR139and reveal a role for POLR2Min the MIR139-silencing mechanism, downstream of MLL-AF9 and PRC2 in AML. In addition, we confirmed these findings in human AML cell lines with different oncogenic aberrations, suggesting that this is a more common oncogenic mechanism in AML. Our results may pave the way for new targeted therapy in AML.
Details
- Language :
- English
- ISSN :
- 08876924 and 14765551
- Volume :
- 36
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- Leukemia
- Publication Type :
- Periodical
- Accession number :
- ejs58208143
- Full Text :
- https://doi.org/10.1038/s41375-021-01461-5